These observations align with previously published data showing that high circulating levels of IL-6 and TNF-α are associated with early venous thromboembolism during IMiD-based therapy, and that both regimen composition and corticosteroid intensity significantly modulate thrombotic risk [30,31]. This evidence concerns the gene TNF and venous thromboembolism.